October 31, 2018 06:37 AM EDTUpdated May 26, 08:50 PM

Gene therapy developer Orchard prices IPO at $14 to raise $200M

ENDPOINTS

UK gene therapy developer Orchard Therapeutics $ORTX priced its initial public offering at $14 (ADS) per share, and is offering about 14.3 million shares, it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gene therapy developer Orchard prices IPO at $14 to raise $200M

ENDPOINTS

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Trump names Johns Hopkins researcher Marty Makary to lead the FDA

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Gene ther­a­py de­vel­op­er Or­chard prices IPO at $14 to raise $200M

ENDPOINTS

Sign up to read this article for free.

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Gene therapy developer Orchard prices IPO at $14 to raise $200M

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Trump names Johns Hopkins researcher Marty Makary to lead the FDA

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?